Literature DB >> 21523855

Comprehensive prediction of mRNA splicing effects of BRCA1 and BRCA2 variants.

Eliseos J Mucaki1, Peter Ainsworth, Peter K Rogan.   

Abstract

Variants of uncertain significance (VUS) in the BRCA1 and BRCA2 genes potentially affecting coding sequence as well as normal splicing activity have confounded predisposition testing in breast cancer. Here, we apply information theory to analyze BRCA1/2 mRNA splicing mutations categorized as VUS. The method was validated for 31 of 36 mutations known to cause missplicing in BRCA1/2 and all 26 that do not alter splicing. All single-nucleotide variants in the Breast Cancer Information Resource (BIC; Breast Cancer Information Core Database; http://research.nhgri.nih.gov/bic; last access June 1, 2010) were then analyzed. Information analysis is similar in sensitivity to other predictive methods; however, the thermodynamic basis of the theory also enables splice-site affinity to be determined accurately, which is important for assessing mutations that render natural splice sites partially functional and competition between cryptic and natural splice sites. We report 299 of 2,071 single-nucleotide BIC mutations that are predicted to significantly weaken natural sites and/or strengthen cryptic splice sites, 171 of which are not designated as splicing mutations in the database. Splicing alterations are predicted for 68 of 690 BRCA1 and 60 of 958 BRCA2 mutations designated as VUS. These analyses should be useful in prioritizing suspected mutations for downstream expression studies and for predicting aberrantly spliced isoforms generated by these mutations.
© 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21523855     DOI: 10.1002/humu.21513

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  15 in total

1.  Differential expression of alternatively spliced transcripts related to energy metabolism in colorectal cancer.

Authors:  Anastasiya Vladimirovna Snezhkina; George Sergeevich Krasnov; Andrew Rostislavovich Zaretsky; Alex Zhavoronkov; Kirill Mikhailovich Nyushko; Alexey Alexandrovich Moskalev; Irina Yurievna Karpova; Anastasiya Isaevna Afremova; Anastasiya Valerievna Lipatova; Dmitriy Vladimitovich Kochetkov; Maria Sergeena Fedorova; Nadezhda Nikolaevna Volchenko; Asiya Fayazovna Sadritdinova; Nataliya Vladimirovna Melnikova; Dmitry Vladimirovich Sidorov; Anatoly Yurievich Popov; Dmitry Valerievich Kalinin; Andrey Dmitrievich Kaprin; Boris Yakovlevich Alekseev; Alexey Alexandrovich Dmitriev; Anna Viktorovna Kudryavtseva
Journal:  BMC Genomics       Date:  2016-12-28       Impact factor: 3.969

2.  ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes.

Authors:  Amanda B Spurdle; Sue Healey; Andrew Devereau; Frans B L Hogervorst; Alvaro N A Monteiro; Katherine L Nathanson; Paolo Radice; Dominique Stoppa-Lyonnet; Sean Tavtigian; Barbara Wappenschmidt; Fergus J Couch; David E Goldgar
Journal:  Hum Mutat       Date:  2011-11-03       Impact factor: 4.878

3.  Comparison of mRNA splicing assay protocols across multiple laboratories: recommendations for best practice in standardized clinical testing.

Authors:  Phillip J Whiley; Miguel de la Hoya; Mads Thomassen; Alexandra Becker; Rita Brandão; Inge Sokilde Pedersen; Marco Montagna; Mireia Menéndez; Francisco Quiles; Sara Gutiérrez-Enríquez; Kim De Leeneer; Anna Tenés; Gemma Montalban; Demis Tserpelis; Toshio Yoshimatsu; Carole Tirapo; Michela Raponi; Trinidad Caldes; Ana Blanco; Marta Santamariña; Lucia Guidugli; Gorka Ruiz de Garibay; Ming Wong; Mariella Tancredi; Laura Fachal; Yuan Chun Ding; Torben Kruse; Vanessa Lattimore; Ava Kwong; Tsun Leung Chan; Mara Colombo; Giovanni De Vecchi; Maria Caligo; Diana Baralle; Conxi Lázaro; Fergus Couch; Paolo Radice; Melissa C Southey; Susan Neuhausen; Claude Houdayer; Jim Fackenthal; Thomas Van Overeem Hansen; Ana Vega; Orland Diez; Rien Blok; Kathleen Claes; Barbara Wappenschmidt; Logan Walker; Amanda B Spurdle; Melissa A Brown
Journal:  Clin Chem       Date:  2013-11-08       Impact factor: 8.327

4.  The landscape of alternative splicing in cervical squamous cell carcinoma.

Authors:  Peng Guo; Dan Wang; Jun Wu; Junjun Yang; Tong Ren; Baoli Zhu; Yang Xiang
Journal:  Onco Targets Ther       Date:  2014-12-22       Impact factor: 4.147

Review 5.  Interpretation of mRNA splicing mutations in genetic disease: review of the literature and guidelines for information-theoretical analysis.

Authors:  Natasha Caminsky; Eliseos J Mucaki; Peter K Rogan
Journal:  F1000Res       Date:  2014-11-18

6.  Functional classification of BRCA2 DNA variants by splicing assays in a large minigene with 9 exons.

Authors:  Alberto Acedo; Cristina Hernández-Moro; Álvaro Curiel-García; Beatriz Díez-Gómez; Eladio A Velasco
Journal:  Hum Mutat       Date:  2015-02       Impact factor: 4.878

7.  Splicing mutation analysis reveals previously unrecognized pathways in lymph node-invasive breast cancer.

Authors:  Stephanie N Dorman; Coby Viner; Peter K Rogan
Journal:  Sci Rep       Date:  2014-11-14       Impact factor: 4.379

8.  Comparative in vitro and in silico analyses of variants in splicing regions of BRCA1 and BRCA2 genes and characterization of novel pathogenic mutations.

Authors:  Mara Colombo; Giovanna De Vecchi; Laura Caleca; Claudia Foglia; Carla B Ripamonti; Filomena Ficarazzi; Monica Barile; Liliana Varesco; Bernard Peissel; Siranoush Manoukian; Paolo Radice
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

9.  Interpretation, stratification and evidence for sequence variants affecting mRNA splicing in complete human genome sequences.

Authors:  Ben C Shirley; Eliseos J Mucaki; Tyson Whitehead; Paul I Costea; Pelin Akan; Peter K Rogan
Journal:  Genomics Proteomics Bioinformatics       Date:  2013-03-14       Impact factor: 7.691

10.  A unified analytic framework for prioritization of non-coding variants of uncertain significance in heritable breast and ovarian cancer.

Authors:  Eliseos J Mucaki; Natasha G Caminsky; Ami M Perri; Ruipeng Lu; Alain Laederach; Matthew Halvorsen; Joan H M Knoll; Peter K Rogan
Journal:  BMC Med Genomics       Date:  2016-04-11       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.